Drugs / MK-6183
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02341599 | Dec 2014 → Apr 2015 | impaired renal function disease | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02341599 ↗ |
| Known as | CB-238,614 | “MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.” NCT02341599 ↗ |
| Route | Intravenous | “100 mL intravenous (IV) administration over 1 hour.” NCT02341599 ↗ |